Payment overview · 2025
General Payments
$211.09
15 reported records · 3 companies
Healthcare provider profile · identity verified
Paul D Hamm, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLARION, PA · NPI 1275537862
Verified facts
What the public records show
CMS Open Payments records show Paul D Hamm, D.O. received $211.09 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 80.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $169.27 | 80.2% | 13 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.78 | 11.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.04 | 8.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $211.09 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.17 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $68.10 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $18.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 87 |
| Lisinopril | Lisinopril | 391 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 308 | 82 |
| Gabapentin | Gabapentin | 275 | 55 |
| Metformin Hcl | Metformin Hcl | 268 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 62 |
| Omeprazole | Omeprazole | 258 | 67 |
| Eliquis | Apixaban | 255 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 245 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 40 |
| Tramadol Hcl | Tramadol Hcl | 187 | 40 |
| Jardiance | Empagliflozin | 182 | 28 |
| Furosemide | Furosemide | 175 | 42 |
| Losartan Potassium | Losartan Potassium | 172 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 33 |
| Trazodone Hcl | Trazodone Hcl | 132 | 33 |
| Sertraline Hcl | Sertraline Hcl | 122 | 26 |
| Lorazepam | Lorazepam | 121 | 26 |
| Meloxicam | Meloxicam | 120 | 26 |
| Famotidine | Famotidine | 117 | 34 |
| Bumetanide | Bumetanide | 102 | 22 |
| Allopurinol | Allopurinol | 101 | 19 |
| Carvedilol | Carvedilol | 97 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 94 | 62 |
| Prednisone | Prednisone | 92 | 44 |
| Xarelto | Rivaroxaban | 92 | 13 |
| Irbesartan | Irbesartan | 88 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 27 |
| Clonazepam | Clonazepam | 81 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 78 | 11 |
| Ezetimibe | Ezetimibe | 77 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 21 |
| Simvastatin | Simvastatin | 72 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 12 |
| Spironolactone | Spironolactone | 69 | 14 |
| Clonidine Hcl | Clonidine Hcl | 68 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 16 |
| Donepezil Hcl | Donepezil Hcl | 65 | suppressed |
| Potassium Chloride | Potassium Chloride | 65 | 16 |
| Celecoxib | Celecoxib | 63 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 18 |
| Alprazolam | Alprazolam | 59 | 19 |
| Atenolol | Atenolol | 59 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 12 |
| Montelukast Sodium | Montelukast Sodium | 59 | 19 |
| Methocarbamol | Methocarbamol | 58 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 11 |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 54 | 11 |
| Mupirocin | Mupirocin | 54 | 25 |
| Ozempic | Semaglutide | 54 | 11 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Finasteride | Finasteride | 51 | suppressed |
| Valsartan | Valsartan | 50 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Metformin Hcl Er | Metformin Hcl | 48 | 11 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Glimepiride | Glimepiride | 43 | 13 |
| Rybelsus | Semaglutide | 43 | 15 |
| Amoxicillin | Amoxicillin | 42 | 36 |
| Baclofen | Baclofen | 42 | suppressed |
| Levocarnitine | Levocarnitine | 42 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Nystatin | Nystatin | 38 | 25 |
| Topiramate | Topiramate | 37 | suppressed |
| Meropenem | Meropenem | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Cephalexin | Cephalexin | 34 | 25 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Haloperidol | Haloperidol | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Fluconazole | Fluconazole | 27 | 13 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 26 |
| Clozapine | Clozapine | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Constulose | Lactulose | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Admelog Solostar | Insulin Lispro | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 13 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 16 |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | 12 |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Methylphenidate Hcl Cd | Methylphenidate Hcl | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $211.09 · 15 records | Novo Nordisk Inc | AMS 700, INGREZZA, Ozempic, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error